These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26086755)

  • 1. Mutanome Engineered RNA Immunotherapy (MERIT).
    Hum Gene Ther Clin Dev; 2015 Jun; 26(2):84-6. PubMed ID: 26086755
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination.
    Vormehr M; Schrörs B; Boegel S; Löwer M; Türeci Ö; Sahin U
    J Immunol Res; 2015; 2015():595363. PubMed ID: 26844233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple negative breast cancer: are we scoring a home run?
    El Rassy E; Ibrahim N; Ghosn M
    Future Oncol; 2018 Apr; 14(9):793-796. PubMed ID: 29527949
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials.
    Malla R; Srilatha M; Muppala V; Farran B; Chauhan VS; Nagaraju GP
    J Control Release; 2024 Jun; 370():707-720. PubMed ID: 38744346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.
    Grabbe S; Haas H; Diken M; Kranz LM; Langguth P; Sahin U
    Nanomedicine (Lond); 2016 Oct; 11(20):2723-2734. PubMed ID: 27700619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.
    Moradi A; Pourseif MM; Jafari B; Parvizpour S; Omidi Y
    Pharmacol Res; 2020 Jun; 156():104790. PubMed ID: 32278043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoepitope Vaccines Next Immunotherapy Frontier.
    Cancer Discov; 2016 Feb; 6(2):112. PubMed ID: 26712929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Where do the immune checkpoint inhibitors stand in the management of triple negative breast cancer?
    Rassy EE; Karak FE; Ghosn M
    Immunotherapy; 2018 Feb; 10(4):247-250. PubMed ID: 29421978
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy.
    Finnigan JP; Rubinsteyn A; Hammerbacher J; Bhardwaj N
    Oncology (Williston Park); 2015 Dec; 29(12):970-2, 974-5. PubMed ID: 26676902
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of two different immunotherapies on triple negative breast cancer in animal model.
    Liu X; Hu J; Cao W; Qu H; Wang Y; Ma Z; Li F
    Cell Immunol; 2013; 284(1-2):111-8. PubMed ID: 23973874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-testis genes as candidates for immunotherapy in breast cancer.
    Ghafouri-Fard S; Shamsi R; Seifi-Alan M; Javaheri M; Tabarestani S
    Immunotherapy; 2014; 6(2):165-79. PubMed ID: 24491090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of inflammatory infiltrates in triple negative breast cancer.
    Matsumoto H; Koo SL; Dent R; Tan PH; Iqbal J
    J Clin Pathol; 2015 Jul; 68(7):506-10. PubMed ID: 25750267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients.
    Siliņa K; Zayakin P; Kalniņa Z; Ivanova L; Meistere I; Endzeliņš E; Abols A; Stengrēvics A; Leja M; Ducena K; Kozirovskis V; Linē A
    J Immunother; 2011 Jan; 34(1):28-44. PubMed ID: 21150711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preface.
    Tainsky MA; Morris RT
    Cancer Metastasis Rev; 2015 Mar; 34(1):3. PubMed ID: 25648358
    [No Abstract]   [Full Text] [Related]  

  • 15. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
    Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C
    J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
    Coradini D; Biganzoli E; Ardoino I; Ambrogi F; Boracchi P; Demicheli R; Daidone MG; Moliterni A
    Breast; 2015 Jun; 24(3):294-7. PubMed ID: 25698149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
    Nelson B
    Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
    Shurin MR; Gregory M; Morris JC; Malyguine AM
    Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer that progressed as estrogen receptor-positive skin metastases.
    Lee SM; Kang EJ; Kim JH; Yun JM; Sun DS; Ko YH; Won HS
    Korean J Intern Med; 2015 May; 30(3):411-4. PubMed ID: 25995674
    [No Abstract]   [Full Text] [Related]  

  • 20. The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data.
    Raju R; Paul AM; Asokachandran V; George B; Radhamony L; Vinaykumar M; Girijadevi R; Pillai MR
    Breast Cancer Res; 2014 Dec; 16(6):490. PubMed ID: 25472854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.